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Obstructive (OSA) and central sleep apnea (CSA) are very common in patients with congestive
heart failure (CHF). This is clearly a risk factor for worsening the prognosis of patients.
Treatment of sleep apnea in these patients may stop disease progression. Modern therapy,
primarily central sleep apnea, is provided by adaptive servoventilation (ASV). Short-term
randomized trials have demonstrated that treatment with ASV increased ejection fraction
(EF), reduces sympathetic activity and blood pressure. Unfortunately, there is not enough data
on whether there are effects on mortality and morbidity. Studies of this issue, such as SERVE-
HF and ADVENT-HF, are currently in progress and results are expected. There are other forms
of therapy of OSA like CPAP, oxygen, theophylline, acetazolamide, heart synchronisation
therapy and transplantation. In patients with a predominance of OSA, in addition to previous
methods, there are other recommended forms of therapy like appropriate weight loss,
orthodontic appliances and surgical treatment.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Sleep-disordered breathing (SDB) is common in patients with
congestive heart failure (CHF). SDB can be classiﬁed as 2 types:
central sleep apnea (CSA), often associated with Cheyne–Stokes
breathing (CSA–CSB), followed by obstructive (OSA) or mixed
apnea/hypopnea. This is clearly a risk factor for worsening the
prognosis of patients with heart failure, although usually not
associated with daytime sleepiness. The exact etiology of these
disorders in patients with heart failure is not fully understood.
One of the reasons may be wall thickening and edema of the
larynx and respiratory control instability. OSA may impair
cardiac function by increasing afterload, caused by an increase
in ventricular transmural pressure during breathing and
chronic increase in sympathetic activity. OSA is also associated
with a higher incidence of hypertension, myocardial infarction,
stroke and nocturnal arrhythmias [1,2]. In our article, we
discuss the epidemiology, pathophysiology, diagnosis, and
new trends in the treatment of SDB in heart failure.1.1. Epidemiology of sleep-disordered breathing
in congestive heart failure
Prevalence of SDB in CHF is rather difﬁcult to diagnose. The
case studies used different criterias for the evaluation of
sleep apnea, hypopnea, apnea–hypopnea index (AHI) and
criteria used to differentiate CSA and OSA. Also, the deﬁnition
of CHF is not always the same (systolic or diastolic, different
ejection fraction—EF), etc. According to the studies by Old-
enburg et al. 700 patients with systolic heart failure treated
according to current guidelines, a prevalence of SDB was
discovered in 76% (36% with OSA and 40% with CSA) [3].
Paulino et al. noted that among 316 French patients with
stable heart failure and with an ejection fraction of less than
45% found a prevalence of SDB in 81% (of which 70% had OSATable 1 – Prevalence of SDB in heart failure.
First author Year Number of patients Ejection fractio
Oldenburg 2007 700 ≤40
Paulino 2009 316 ≤45
MacDonald 2008 108 ≤40
Redeker 2010 170 –
Bitter 2009 244 ≤55
Khayat 2009 395 ADHF
Ferreira 2010 103 –
Damy 2012 384 ≤45and 30% had CSA) [4]. MacDonald et al. studied the preva-
lence of SDB in 108 patients with heart failure and an ejection
fraction of less than 40%. SDB was found in 61% (including
30% with OSA and 31% of CSA) [5]. Redeker et al. discovered
SDB in 51% of patients with heart failure with an ejection
fraction of 32714.6 (9% with CSA and 21% with OSA) [6]. Bitter
et al. studied 244 patients with heart failures with a normal
ejection fraction, (EF455%) SDB and found in 69.3% of
patients (39.8% with OSA and 29.5% with CSA) [7]. Khayat
et al. tested 395 patients with acute decompensated heart
failure and found SDB in 75% of patients (57% had OSA and
18% CSA) [8]. Ferreira et al. followed 103 patients with heart
failure with optimal treatment. SDB was found in 72.8% of
patients. (60% of those with OSA and 9.3% with CSA, mixed
apnea was at 30.7% of patients) [9]. Recent studies by Damy
et al. noted among 384 patients with heart failure and with an
ejection fraction ≤45% SDB was discovered present in 88% of
patients (62% with OSA and 26% with CSA) [10] Table 1.2. Pathophysiology of sleep-disordered
breathing in congestive heart failure
OSA in SDB may accompany central sleep apnea episodes at
the end of almost a third of the cases [11]. Direct ﬁbroscopic
observation has shown episodes of the upper airway narrow-
ing and closure during central apneas [12]. This narrowing
could be the effect of a reduction in the muscle structures of
the upper respiratory tract, which is combined with anato-
mical narrowing of the upper airway. Pure OSA may appear
especially in obese patients. Obesity and fat in the neck
region leads to narrowing of the upper airway. Pharyngeal
edema and narrowing may develop during supine sleep with
redistribution causing swelling of the legs. This observation
was supported by the observed improvement in OSA by
diuretic therapy in patients with diastolic heart failure [13].n (EF) (%) SDB deﬁnition SDB Prevalence (OSA, CSA) (%)
AHI≥5 76 (36, 40)
AHI≥10 81 (from which 70 a 30)
AHI≥15 61 (30, 31)
AHI≥5 51 (22, 9)
AHI≥5 69 (40,29)
AHI≥15 75 (57,18)
AHI≥5 73 (60,9)
AHI≥5 88 (62,26)
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closure during sleep. Obstructive apnea and hypopnea
increases negative intrathoracic pressure that increase left
ventricular transmural pressure and afterload. It also
increases venous return and causes right ventricular disten-
tion. There is a deterioration of the left ventricular ﬁlling and
a decreased ejection fraction [14]. Intermittent hypoxemia
during OSA leads to an increase in pressure in the pulmonary
arteries and the sympathetic activation with a consequent
increase in blood pressure [15]. OSA also leads to the forma-
tion of oxidative stress, vascular endothelial dysfunction and
progression of atherosclerosis [16,17] Fig. 1.
It is suspected, that CSA in heart failure is mainly caused by
the instability of the ventilatory control system. Patients with
CSA–CSB have increased response of peripheral and central
chemoreceptors, leading to hyperventilation and hypocapnia.
Patients with CSA–CSB in CHF usually have chronic respiratory
alcalosis from hyperventilation. Hyperventilation often drives
the PCO2 below the apneic threshold, leading to decreased
central respiratory drive. An important factor contributing to
hyperventilation is vagal irritant J-receptor stimulation by
pulmonary venous congestion. This mechanism creates a
typical crescendo–decrescendo type of Cheyne–Stokes breath-
ing [18,19] Fig. 2.3. Diagnosis of sleep-disordered breathing
in congestive heart failure
OSA affects more men than women. The typical patients with
OSA are obese, snoring men who can be sleepy during theFig. 1 – Obstructivday. They are usually tired in the morning, with sleepless
behavioral changes, poor concentration, fatigue and head-
aches. They can acquire erectile dysfunction. Patients with
CSA may develop different symptoms. Patients are not often
overweight and do not snore. They are even less proned to
early fatigue and sleepiness. They can often be subjected to
periodic breathing whilst awake, during exercise and hyper-
ventilation and subsequent hypocapnia. SDB is associated
with a higher incidence of associated diseases—hyperten-
sion, heart failure, arrhythmias, stroke, myocardial infarc-
tion, chronic renal insufﬁciency and sudden cardiac death.
The gold standard in laboratory diagnosis is the nocturnal
polysomnographic examination rated by an experienced
sleep technician. During polysomnography EEG, ECG, EMG
of the chin muscle, electro-oculogram (EOG), the air ﬂow
during breathing, breathing movements of the chest and
abdomen, breathing sounds, oxygen saturation of hemoglo-
bin, the movements of the legs and body positions are all
monitored. The patient is monitored by a video camera.
Beforehand, we ask patients for prior history with the
presence of snoring, fatigue, increased daytime sleepiness
or poor sleep quality. Also, a history of nocturnal angina
pectoris, dyspnea, arrhythmia apnea during sleep should be
prescribed for a departure to the sleep laboratory. We can
also use questionnaires such as the Epworth Sleepiness Scale
for the evaluation of sleep [20]. A variety of different kinds of
portable polysomnography devices are also available to
diagnose SDB. In-home respiratory telemonitoring can reduce
costs compared to traditional polysomnography [21]. It is
suspected that CSA–CSB may also result in the absence of a
drop in pressure during sleep within 24-h monitoring cyclee sleep apnea.
Fig. 2 – Cheyne–Stokes respiration.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 1 – e 4 1 8e414(non-dipping), a high variability in heart rate and a reduction
in the oxygen saturation of hemoglobin [22].4. Treatment of sleep-disordered breathing
in congestive heart failure
The ﬁrst condition is the optimal treatment for CHF. As already
mentioned, diuretics may improve OSA in heart failure. The
same has been shown for captopril and carvedilol [23,24].
4.1. Continuous positive airway pressure (CPAP)
Continuous positive airway pressure (CPAP) has been suc-
cessfully used to treat OSA in stable CHF. This method was
used in the treatment of OSA for the ﬁrst time in 1981 by
Sullivan et al. [25]. This ventilation unit generates continuous
pressure to which the patient is connected by a nasal or facial
mask. The mask has a spontaneous expiratory valve allowing
exhalation. Apnea, hypopnea and awakenings should disap-
pear when the surface pressure is properly adjusted [26].
Setting the correct level of CPAP is done via diagnostic
titration. This is usually done in a sleep laboratory under
the supervision of an experienced sleep technician. Accord-
ing to the American Academy of Sleep Medicine, the mini-
mum recommended CPAP is 4 cm H2O. The maximum
recommended pressure is 20 cm H2O. CPAP should be
increased by at least 1 cm H2O with an interval of at least
5 min in order to eliminate respiratory problems. CPAP
should be increased after two or three obstructive apnea
hypopnea. CPAP should be increased by at least 1 min ofcontinuous snoring [27]. We can also use AutoCPAP to per-
form CPAP titration. AutoCPAP airﬂow automatically evalu-
ates and adjusts the amount of pressure. It is used for
diagnostic titration. The data downloaded from the device
can determine the optimal level of CPAP pressure [28,29].
CPAP therapy has been successfully used in the treatment of
OSA in heart failure. CPAP use has been shown to improved
EF in some studies [30,31]. Some studies have not shown this
effect [32]. Negative results in this study may be explained by
the low inspiratory pressure. A meta-analysis of randomized
controlled trials comparing studies with nocturnal CPAP
therapy in patients with heart failure and CSA–CSF decreased
AHI and increased EF (16 studies). There was also an
increased EF, AHI and heart transplant free survival [32].
The Canadian Contionuous Positive Airway Pressure Trial for
Congestive Heart Failure Patients with Central Sleep Apnea
(CANPAP) studied 258 CHF patients with CHF and nocturnal
CPAP. They compared 128 patients with and 130 patients
without CPAP. The CPAP group had the expected decrease in
AHI, increase in EF and a walking distance in 6 min compared
to the branch without CPAP. There was no difference in the
number of hospitalizations, quality of life or transplant-free
survival. There was actually an increase in early mortality in
patients with CPAP. The main discovery of this study was
that there was not an adequate reduction in AHI (AHI was
19 events/h) [33]. Suboptimal treatments were the main
limitations of this study. In a post trial analysis by Arzt
et al., it was found that patients who were ventilated
effectively achieved AHI o15 (about 57% of patients). These
patients had a longer transplant-free survival rate than those
of the sub-optimally treated group [34].
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Bi-level positive pressure ventilation (BIPAP) is another
option to use. When this method is adjusted, inspiratory
and expiratory pressure levels are adjusted during the BIPAP
set up. Inspiratory pressure (IPAP) is always higher than the
expiratory pressure (EPAP). BIPAP is indicated in patients who
require more than the inspiratory pressure CPAP or positive
pressure at the end of expirium (PEEP). BIPAP can be used in
two modes (S—spontaneous) and (ST—spontaneous-timed).
BIPAP reduces the OSA AHI more than CPAP or untreated
patients [35]. BIPAP in patients with nonhypercapnic CSA
can cause hyperventilation (especially at high difference
between IPAP and EPAP) and thereby decreasing blood pCO2.
PCO2 reduction below a certain trigger level may deteriorate
CSA [36].
4.3. Treatment using adaptive servoventilation (ASV)
ASV is made up of bi-level ventilation, which leads to the
automatic adjustments in support pressure with every breath
by the patient's own respiratory effort. ASV is a relatively new
method in the treatment of SDB. ASV provides ﬁxed EPAP
that is manually titrated from 4 cm H2O and the IPAP
variable, which allows variations in pressure between
5–30 cm H2O. Fixed EPAP and IPAP removes OSA and CSA
hypoventilation. The initial setting is EPAP 4 cm H2O and
maximum Pressure Support 9–10 cm H2O. If the patient's own
respiratory effort is reduced, the device adds inspiratory
pressure, so as to ensure a 90% baseline ventilation. The
maximum pressure limit for IPAP is 30 cm H2O. This system
is especially suitable for patients with CSA and CSB–CSA
mainly because it does not cause hyperventilation and a
subsequent reduction in pCO2. ResMed ASV (AutoSet CS, CS2,
VPAP Adapt, AdaptSV) produces expiratory pressure, which is
set to open upper airway obstruction. This device is trying to
set the 90% calculated ventilatory support in a 3-min window,
ensuring minimization of hypo- and hyperventilation.
ResMed ASV provides pressure support between 3 and
15 cm H2O, and if that is not sufﬁcient, it increases respiratory
rate. Respironics ASV (BiPAP autoSV) calculates pressure
support in a 4-min window and minimizes hypo-and hyper-
ventilation. Like ResMed ASV EPAP serves to stabilize the
upper airway obstruction and inspiratory pressure is
increased if spontaneous inspiratory pressure is below the
target value [37]. In a study of Hastings et al., eleven patients
were studied with stable heart failure and sleep apnea.
Patients were treated with ASV for six months, and compared
to eight patients without ASV. Patients with ASV achieved a
reduction in sleep apnea, an improved EF and quality of life
[38]. Bitter et al. conducted a study with 60 patients with
heart failure and normal EF. A total of 39 patients agreed to
treatment by ASV. The control group consisted of 21 patients
who refused ASV. ASV improved AHI, diastolic function and
loading capacity [39]. Carnevale et al. retrospectively studied
74 patients with heart failure and CSA treated with ASV for
36718 months. There was an improvement in NYHA scores,
Epworth sleepiness scale and blood gases. ASV was well
tolerated and very effective [40]. A meta-analysis has shown
that the ASV improved EF by 6%, decreased the AHI to12–23 events/h compared to CPAP [37]. The SERVE-HF study
is a large, multicenter, randomized trial which began recruit-
ment in 2008. This study is actively involved in our work-
place. The primary objective of the study is to demonstrate
the long-term effect of ASV on morbidity and mortality in
patients with heart failure and CSA [41]. ADVENT-HF study is
another ongoing study. It monitors ASV effects on mortality
and hospitalizations in patients with heart failure and sleep
apnea (OSA and CSA). The earliest results will be expected
in 2015 [37].
4.4. Cardiac resynchronization therapy (CRT)
Cardiac resynchronization therapy improves cardiac output
contraction by the coordination of the right and left ventricle.
This leads to a reduction in AHI and improves SDB in patients
with heart failure and SDB. Gabor et al. studied 28 patients
eligible for CRT. CSA–CSB was found in 12 (43%) patients. CRT
was started in 10 patients. Six patients were found to have
reduced the severity of CSA–CSB. Improvements in heart
failure reduced hypoventilation and hypocapnia [42]. Another
study by Oldenburg et al. studied 77 patients with heart
failure suitable for CRT. CSA–CSB was detected in 36 (47%).
CRT improved AHI and satO2 only in patients with CSA–CSB
[43]. Kara et al. studied 12 patients with CSR. They compared
the AHI in patients with CSR on and off for 3 nights. There
was a reduction of AHI in patients with activated CSR [44].
4.5. Cardiac transplantation
Thirteen patients with heart failure and CSA were studied
before and after heart transplantation. It has been found to
improve the SDB, but CSA persisted in 3 patients and OSA in 4
patients [45]. Similarly, 36% of patients with heart failure who
have had a heart transplant developed OSA. It was probably
due to the accumulation of fat due to steroids intake after
transplantation [46].
4.6. Oxygen therapy
The administration of oxygen can reduce the CSA in patients
with heart failure. Oxygen administration in patients with
heart failure and CSA were observed in several studies.
Sasayama et al. studied nocturnal home oxygen administra-
tion for a period of one year in patients with heart failure and
CSA. There was a reduction of AHI, increased nocturnal
saturation, an improvement in the quality of life, NYHA
reduction and increased EF [47]. Toyama et al. watched the
effect of nocturnal home oxygen administration in patients
with heart failure and CSA. AHI, peak VO2 and the increase in
EF was improved [48]. Krachman et al. studied the inﬂuence
of nocturnal oxygen administration for one month to
improve EF. They found that despite improvements of AHI,
there were no improvements in EF [49]. Oxygen improves EF
and the quality of life in patients with heart failure. The
mechanism of action is not clear. Each patient with signiﬁ-
cant hypoxemia should be a candidate for the oxygen test.
The optimal quantity of the oxygen should be titrated during
polysomnography.
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It has been shown that increased levels of CO2 during
inspiration reduces the amount of CSA and CSB–CSA and
reduces the AHI. This can be achieved either by increasing
dead space connecting the plastic bag or by the direct
administration of CO2 via facial masks. It keeps the CO2 level
above the level that leads to the starting of apnea. The
desired effect can last longer by a minimal increase in CO2
(about 2 mmHg). Szollosi et al. tested the administration of
100% CO2 in patients with heart failure and CSA. Adminis-
tration of CO2 led to a reduction in CSA, but did nothing to
reduce the number of arousals [50]. Lorenzo-Filho et al.
watched the effect of inhaled CO2 and oxygen on Cheyne–
Stokes respiration in patients with heart failure. They found a
decrease in AHI and an increase in satO2 after the adminis-
tration of CO2. Oxygen only increased satO2 and did not
decrease AHI [51]. It has been shown that increased levels
of CO2 during inspiration reduces the amount of CSA and
CSB–CSA and reduces the AHI. Treatment with CO2 is not
currently available due to the inability to monitor the levels
of exhaled and rebreathed CO2. An unimproved number of
arousals leading to sympathetic activation were detected
which is a risk factor for cardiovascular disease.4.8. Drug treatment
Theophylline and acetazolamide can be used as therapy for
sleep apnea. Oral theophylline administered for 5 days
improved SDB in patients with stable heart failure [52,53].
The mechanism of how theophylline affects sleep apnea is
not known. Since they are not long-term controlled studies,
theophylline is not used in the treatment of OSA. Theophyl-
line also has a pro-arrhythmic potential which is not recom-
mended for heart failure. Acetazolamide administered every
evening for 6 days resulted in a signiﬁcant reduction in AHI
and sleep quality [54]. Acetazolamide is a mild diuretic and
can lessen heart failure. It also causes metabolic acidosis,
which stimulates breathing. This reduces levels of pCO2 and
leads to a reduction in CSA [55].SDB
OSA
Weight loss
Positional therapy
Oral appliance
Surgical treatment
CPAP
BIPAP
CPA
ASV
Fig. 3 – Expected SDB schem5. Further treatment of patients with OSA
prevalence
Other methods to improve OSA are reductions in the weight
of obese patients, avoiding sleeping on your back (tennis balls
sewn into the back of pajamas), smoking prevention, alcohol
and the use of benzodiazepines before bedtime.
5.1. Oral appliance therapy
Oral appliances therapy is using a removable protractor—the
orthodontic appliance, which is attached only at night. They
are suggested for mild to medium degrees of OSA in patients
who cannot tolerate CPAP.
5.2. Surgical therapy
Surgical therapy is recommended for the removing of anato-
mical obstacles. In childhood, it is tonsillectomy and adenoi-
dectomy. Septoplasty is indicated in the adult age then patient
has a deviation of the nasal septum. It is mainly used before
CPAP. Uvulopalatopharyngoplasty (UPPP) reduces pharyngeal
tissue and further strengthens the scar. Greater achievements
are observed in patients with mild to moderate OSA who are
not obese. Laser uvuloplasty (laser assisted uvuloplasty—
LAUP) is used to remove parts of the soft palate and scarring.
It is effective in the treatment of rhonchopathy. Other possi-
bilities are reconstructive operations of the lower and upper
jaw: (1) advancement of the m.genioglossus (genioglossus
advancement—GA) (2) mandibular movement (3) maxilloman-
dibular movement another method is radioblation to the base
of the tongue and soft palate. A deﬁnitive solution to OSA is
tracheostomy. However, it signiﬁcantly reduces the quality of
life and therefore is not used for OSA anymore [56] Fig. 3.6. Conclusion
Heart failure and SDB are common diseases which often
occur simultaneously. The simultaneous occurrence of bothCSA-CSB
P
Oxygen
Acetazolamide
Teophylline
CRT
RHB
        Heart
transplantation
a therapy in heart failure.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 1 – e 4 1 8 e417diseases has a worse prognosis and may worsen mortality.
Optimal treatment of heart failure, according to international
treatment recommendations is basic for SDB. CPAP can
improve AHI and increase EF in patients with heart failure
and SDB. A new treatment using adaptive servoventilation is
a promising method that can be more successful than
conventional treatment with CPAP. The results of the new
long-term studies are expected to evaluate the effect of ASV
on long-term survival.Acknowledgments
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